Renoprotective Effects of MIT ‐001 in Ischemia–Reperfusion Injury: Modulation of Ferroptosis, ROS and Fibrotic Markers
Journal of Cellular and Molecular Medicine · 2025
DOI: 10.1111/jcmm.70914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2025. Verfasst von Jin Ah Shin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Ferroptosis, Reperfusion Injury, Reactive Oxygen Species, Protective Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chungnam National University Hospital Research Fund, 2024, National Research Foundation of Korea, Clinical Research Institute Grant funded by The Catholic University of Korea Daejeon St. Mary's Hospital.
Abstract (Originalsprache)
Renal ischemia–reperfusion injury (IRI) is a key driver of the progression from acute kidney injury (AKI) to chronic kidney disease (CKD), primarily through mechanisms involving oxidative stress, ferroptosis, and inflammation that promote fibrotic remodelling. This study investigates the therapeutic potential of MIT‐001, a mitochondria‐targeted reactive oxygen species (ROS) scavenger, in mitigating renal IRI. In vitro, MIT‐001 attenuated ferroptotic cell death and fibrotic responses in HK‐2 cells challenged with TGF‐β or RSL3. MIT‐001 restored GPX4 expression and activity, activated Nrf2 signalling, reduced lipid ROS and suppressed fibrogenic markers (α‐SMA, Snail, collagen IV), while preserving E‐cadherin levels. In a bilateral renal IRI mouse model, administration of MIT‐001 significantly improved renal function and histology. Oxidative stress (DHE staining), apoptosis (TUNEL) and ferroptosis (4‐HNE, xCT, GPX4) were markedly reduced. Additionally, MIT‐001 inhibited the NF‐κB/HMGB1 inflammatory axis and enhanced antioxidant defence via the Nrf2/HO‐1 pathway, resulting in decreased immune infiltration and fibrosis. These findings demonstrate that MIT‐001 confers renal protection by concurrently targeting oxidative stress, ferroptosis and inflammation, underscoring its promise as a therapeutic strategy to prevent AKI‐to‐CKD progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Science, Chungnam National University, Daejeon, Republic of Korea.
- Division of Nephrology, Department of Internal Medicine, Daejeon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Clinical Research Institute, Daejeon St Mary's Hospital, Daejeon, Republic of Korea.
- Department of Nephrology, Chungnam National University Hospital, Daejeon, Republic of Korea.
- Mitoimmune Therapeutics Inc., Seoul, Republic of Korea.
- Hanmi Pharmaceutical, Hwaseong-si, Republic of Korea.
ORCID-Profile: Dae Eun Choi
Förderung
- Chungnam National University Hospital Research Fund, 2024
- National Research Foundation of Korea
- Clinical Research Institute Grant funded by The Catholic University of Korea Daejeon St. Mary's Hospital
- Korean Nephrology Research Foundation
Zitieren
APA
Shin, J. A., Hwang, Y., Park, H., Choi, H., Chang, Y. K., Na, K. R., Kim, S. H., Kim, J. Y., Ham, Y. R., & Choi, D. E. (2025). Renoprotective Effects of MIT ‐001 in Ischemia–Reperfusion Injury: Modulation of Ferroptosis, ROS and Fibrotic Markers. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70914
Vancouver
Shin JA, Hwang Y, Park H, Choi H, Chang YK, Na KR, et al. Renoprotective Effects of MIT ‐001 in Ischemia–Reperfusion Injury: Modulation of Ferroptosis, ROS and Fibrotic Markers. Journal of Cellular and Molecular Medicine. 2025. doi:10.1111/jcmm.70914
BibTeX
@article{Shin2025,
author = {Shin, Jin Ah and Hwang, Yunkyeong and Park, Hyerim and Choi, Hyunsu and Chang, Yoon-Kyung and Na, Ki Ryang and Kim, Soon Ha and Kim, Jae Young and Ham, Young Rok and Choi, Dae Eun},
title = {Renoprotective Effects of MIT ‐001 in Ischemia–Reperfusion Injury: Modulation of Ferroptosis, ROS and Fibrotic Markers},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
doi = {10.1111/jcmm.70914}
}
EUVIMED